Get the Stockscreener App
2.605
3.17%
0.08
After Hours:
2.59
-0.015
-0.58%
Galectin Therapeutics Inc stock is traded at $2.605, with a volume of 99,552.
It is up +3.17% in the last 24 hours and down -7.62% over the past month.
See More
Previous Close:
$2.525
Open:
$2.55
24h Volume:
99,552
Relative Volume:
0.80
Market Cap:
$138.59M
Revenue:
-
Net Income/Loss:
$-41.07M
P/E Ratio:
-3.947
EPS:
-0.66
Net Cash Flow:
$-32.97M
1W Performance:
+2.36%
1M Performance:
-7.62%
6M Performance:
-22.01%
1Y Performance:
+29.60%
1-Day Range:
$2.52
$2.62
1-Week Range:
$2.45
$2.65
52-Week Range:
$1.555
$4.2684
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
Non-Alcoholic Steatohepatitis Market to Show Remarkable - openPR
Psoriasis Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
Liver Cirrhosis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Recent Developments | Astrazeneca, Bayer, Sanofi, Pfizer, Merck, Novartis - Barchart
Liver Cirrhosis Pipeline Trends 2024: Clinical Trials, - openPR
LIVER CIRRHOSIS MARKET TO GROW AT A SUBSTANTIAL GROWTH RATE - openPR
Galectin therapeutics director Eldred Kary buys $1,300 in stock By Investing.com - Investing.com South Africa
Galectin therapeutics director Eldred Kary buys $1,300 in stock - Investing.com
Galectin therapeutics director Freeman buys $27,000 in stock By Investing.com - Investing.com Canada
Galectin therapeutics director Freeman buys $27,000 in stock - Investing.com
Galectin Therapeutics Inc. (NASDAQ:GALT) Director Purchases $13,500.00 in Stock - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Upgraded to Hold at StockNews.com - Defense World
Application Monitoring Suites Market Size and Industry Overview - News in Assen
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - The Manila Times
Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: - openPR
Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Statistics, Drugs, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail
Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail
Nonalcoholic Steatohepatitis Treatment Market Size, Innovations Driving Market Evolution (2024-2034) - IndiaPolitics.com
Marshall Wace LLP Buys New Shares in Security National Financial Co. (NASDAQ:SNFCA) - Defense World
Marshall Wace LLP Cuts Stock Holdings in ARC Document Solutions, Inc. (NYSE:ARC) - Defense World
AXT, Inc. (NASDAQ:AXTI) Stock Holdings Trimmed by Marshall Wace LLP - Defense World
The Manufacturers Life Insurance Company Has $951,000 Stock Holdings in Huntsman Co. (NYSE:HUN) - Defense World
Marshall Wace LLP Buys New Holdings in Hanesbrands Inc. (NYSE:HBI) - Defense World
Research Analysts’ Updated EPS Estimates for October 6th (APVO, CNP, FDX, FLNT, FRD, GALT, HOPE, KBR, LSXMK, NVGS) - Defense World
Galectin Therapeutics (NASDAQ:GALT) Rating Increased to Hold at StockNews.com - Defense World
Galectin Therapeutics (NASDAQ:GALT) Upgraded at StockNews.com - MarketBeat
Global Non-Alcoholic Steatohepatitis Treatment Market Overview And Statistics For 2024-2033 - EIN News
Ipsen's IQIRVO Approval Has Intensified the Primary Biliary Cholangitis Market Space | DelveInsight - The Malaysian Reserve
Rhumbline Advisers Purchases New Holdings in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference - The Manila Times
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra - The Manila Times
Galectin Therapeutics (FRA:PHPN) Interest Expense : €-3.71 Mil (TTM As of Jun. 2024) - GuruFocus.com
Galectin Therapeutics (FRA:PHPN) Change In Prepaid Assets : €-0.16 Mil (TTM As of Jun. 2024) - GuruFocus.com
StockNews.com Lowers Galectin Therapeutics (NASDAQ:GALT) to Sell - MarketBeat
Bank of New York Mellon Corp Purchases Shares of 64,423 Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin 3 Market: Report Trends and Future Forecast Until (2024-2034) - Apiculture Market: Report ...
Global Non Alcoholic Steatohepatitis Market to Hit $ 108428.91 Million by 2032, Growing at 60.1% CAGR - 대구포스트
Galectin Therapeutics (FRA:PHPN) Enterprise Value : €217.44 Mil (As of Sep. 21, 2024) - GuruFocus.com
Galectin Therapeutics (NASDAQ:GALT) Upgraded to “Hold” at StockNews.com - Defense World
Cirrhosis Pipeline Insights, Clinical Trials, Treatment Drugs, and Companies 2024 - openPR
Commonwealth Equity Services LLC Buys 367,610 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Commonwealth Equity Services LLC Purchases 367,610 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - MarketBeat
Head-To-Head Analysis: Galera Therapeutics (NASDAQ:GRTX) & Galectin Therapeutics (NASDAQ:GALT) - Defense World
Non-Alcoholic Steatohepatitis Treatment Market Insights Discussed Regarding Report 2024: Detailed Analysis ... - WhaTech
Galectin Therapeutics Unveils Future Plans and Drug Potential - TipRanks
Hepatic Cirrhosis Market: Epidemiology, Therapies, - openPR
Short Interest in Galectin Therapeutics Inc. (NASDAQ:GALT) Increases By 6.4% - Defense World
North America Galectin Inhibitor Therapeutics Market By Application : Industry Analysis and Forecast 2031 - அக்னி செய்திகள்
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Rectify Pharmaceuticals Appoints Pol Boudes as Chief Medical Officer - Yahoo Finance
Galectin Therapeutics Inc. (NASDAQ:GALT) Sees Significant Growth in Short Interest - MarketBeat
Its Stock Has Paid Off Big Time For Galectin Therapeutics Inc - SETE News
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Galectin Therapeutics Inc Stock (GALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FREEMAN KEVIN D | Director |
Oct 17 '24 |
Buy |
2.64 |
1,300 |
3,432 |
34,769 |
| FREEMAN KEVIN D | Director |
Oct 16 '24 |
Buy |
2.70 |
5,000 |
13,500 |
80,000 |
| FREEMAN KEVIN D | Director |
Oct 16 '24 |
Buy |
2.70 |
5,000 |
13,500 |
33,469 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):